An experimental medicine from the Sanofi and Regeneron Pharmaceuticals MPOC produced results mixed in a pair of studies, companies said on Friday, sending actions of the two companies at the start of early and pre-commercial negotiations.
The drug, called Itepekimab, has great hopes while businesses are looking for the next medication that can produce the success observed with Dupixent, their joint superproduction. Dupixent is approved for a number of immune mediation diseases and has taken the green light for MPOC last year.
Sanofi shares slipped around 5% on Friday morning. In American pre-commercial exchanges, Regeneron’s actions have dropped by more than 10%.
This article is exclusive to stat + subscribers
Unlock this article – plus daily coverage and analysis of the biotechnological sector – in SUT +subscription.
Do you already have an account? Connect
Show all plans
To read the rest of this story, subscribe to Stat +.
Get down
